Evaluation of urinary XIAP as a diagnostic biomarker of carcinoma of urinary bladder

Tumor Biology

Volumn 35, Issue 8, 2014, Pages 8243-8248

  Srivastava, A K ^a   Singh, P K ^a   Singh, D ^a   Dalela, D ^a   Rath, S K ^b   Goel, M M ^a   Bhatt, M L B ^c  

^a KING GEORGE'S MEDICAL UNIVERSITY   (India)

^b Research Institute Forests and Rangelands   (India)

^c RML Institute of Medical Sciences   (India)

Author keywords

Noninvasive diagnosis; Urinary Biomarker; Urinary bladder cancer; XIAP

Indexed keywords

TUMOR MARKER; X LINKED INHIBITOR OF APOPTOSIS; XIAP PROTEIN, HUMAN;

ADULT; AGED; CYTOLOGY; FEMALE; HUMAN; MALE; MIDDLE AGED; PATHOLOGY; RECEIVER OPERATING CHARACTERISTIC; URINARY BLADDER NEOPLASMS; URINE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; MALE; MIDDLE AGED; ROC CURVE; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS; URINE; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

EID: 84922394604     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1007/s13277-014-2026-6     Document Type: Article

References (27)

1. Siegel R, Ward E, Brawley O, et al. Cancer Statistics, 2011. The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011;61:212–6.
2. Agarwal PK, Black PC, Kamat AM. Considerations on the use of diagnostic markers in management of patients with bladder cancer. World J Urol. 2008;26:39–44.
3. Grossfeld GD, Carroll PR. Evaluation of asymptomatic microscopic hematuria. Urol Clin N Am. 1998;25:661–6.
4. Mohr DN, Offord KP, Owen RA, et al. Asymptomatic microhematuria and urologic disease. A population-based study. JAMA. 1986;256(2):224–9.
5. Konety BR, Getzenberg RH. Urine based markers of urological malignancy. J Urol. 2001;165:600–11.
6. Goebell PJ, Groshen SL, Schmitz-Drager BJ. Guidelines for development of diagnostic markers in bladder cancer. World J Urol. 2008;26:5–11.
7. Kausch I, Bohle A. Bladder cancer. II. Molecular aspects and diagnosis. Eur Urol. 2001;39:498–506.
8. Srivastava AK, Singh PK, Srivastava K, Singh D, Dalela D, Rath SK, et al. Diagnostic role of survivin in urinary bladder cancer. Asian Pac J Cancer Prev. 2013;14(1):81–5.
9. Srivastava AK, Singh PK, Singh P, Singh D, Bhatt MLB, Dalela D, et al. Clinical experience with UCA 1 as a biomarker for non-muscular invasive bladder cancer. Eur Urol Suppl. 2011;10(2):74.
10. Holcik M, Gibson H, Korneluk RG. XIAP: apoptotic brake and promising therapeutic target. Apoptosis. 2001;20:253–61.
11. Parton M, Krajewski S, Smith I, et al. Coordinate expression of apoptosis-associated proteins in human breast cancer before and during chemotherapy. Clin Cancer Res. 2002;8:2100–8.
12. Alas S, Ng CT, Bonavida B. Rituximab modifies the cisplatin-mitochondrial signaling pathway, resulting in apoptosis in cisplatin-resistant non-Hodgkin’s lymphoma. Clin Cancer Res. 2002;8:836–41.
13. Mizutani Y, Nakanishi H, Li YN, et al. Overexpression of XIAP expression in renal cell carcinoma predicts a worse prognosis. Int J Oncol. 2007;30:919–25.
14. Takeuchi H, Kim J, Fujimoto A, et al. X-linked inhibitor of apoptosis protein expression level in colorectal cancer is regulated by hepatocyte growth factor/C-Met pathway via Akt signaling. Clin Cancer Res. 2005;11(21):7621–8.
15. Li M, Song T, Yin ZF, et al. XIAP as a prognostic marker of early recurrence of nonmuscle invasive bladder cancer. Chin Med J (Engl). 2007;120(6):469–73.
16. Wang L, Bi Y, Zeng F, et al. Expression of X-linked inhibitor of apoptosis protein and its effect on chemotherapeutic sensitivity of bladder carcinoma. J Huazhong Univ Sci Technol Med Sci. 2007;27(3):285–7.
17. Bilim V, Kasahara T, Hara N, et al. Role of XIAP in the malignant phenotype of transitional cell cancer (TCC) and therapeutic activity of XIAP antisense oligonucleotides against multidrug-resistant TCC in vitro. Int J Cancer. 2003;103(1):29–37.
18. Sobin LH, Wittekind C. TNM classification of malignant tumors. 6th ed. New York: Wiley; 2002.
19. Epstein JI, Amin MB, Reuter VR, et al. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol. 1998;22:1435–48.
20. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative pcr and the 22-ΔΔcT method. Methods. 2001;25:402–8.
21. Bewick V, Cheek L, Ball J. Statistics review 13: receiver operating characteristic curves. Crit Care. 2004;8:508–12.
22. Shelley MD, Mason MD, Kynaston. Intravesical therapy for superficial bladder cancer: a systematic review of randomized trials and meta-analyses. Cancer Treat Rev. 2010;36:195–205.
23. American Cancer Society. Cancer facts & figures 2012. Atlanta: American Cancer Society; 2012.
24. Jemal A, Siegel R, Ward E. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225–49.
25. Consolidated report of population-based cancer registries 2001-2004. National Cancer Registry Programme (Indian Council of Medical Research), Bangalore, 2006.
26. Kumar A, Kumar R, Gupta NP. Comparison of NMP22 BladderChek test and urine cytology for the detection of recurrent bladder cancer. Jpn J Clin Oncol. 2006;36(3):172–5.
27. Shafat I, Pode D, Peretz T. Clinical significance of urine heparanase in bladder cancer progression. Neoplasia. 2008;10:125–30.